Correlation between CD133 and EGFR Expression with Grading of Ovarian Carcinoma

Abstract

Background
Ovarian carcinoma account for 90% of all malignant ovarian tumors. Epidermal Growth Factor Receptor (EGFR), also known as
ErbB1/HER1, has an important role in tumor cell proliferation. CD133 is a marker for hematopoietic stem cell and it is involved in tumor
cell proliferation, self renewal and cell differentiation. The objective to analyze the expression of CD 133 and EGFR in high grade and
low grade ovarian carcinoma, and to determine the correlation between the expression of CD133 and EGFR expression in ovarian
carcinoma.
Methods
The study was conducted with observational and cross sectional method on paraffin blocks of patients diagnosed as ovarian
carcinoma from 1 January until 31 December 2017 in Dr. Soetomo Hospital. Ovarian carcinoma was divided into 2 grade, low grade
and high grade. Immunohistochemistry for EGFR and CD133 was performed. Immuno-reactive Score (IRS) was applied to evaluate
the expression of EGFR and CD133. The difference expression of CD133 and EGFR in low grade and high grade ovarian carcinoma
was analyzed with Mann-Whitney test. Correlation between CD133 with EGFR was analyzed with Spearman test.
Results
There were significant difference in expression of CD133 (p=0.0001) and EGFR (p=0.0005) in high grade and low grade Ovarian
Carcinoma. There was significant positive correlation between CD133 and EGFR expression in Ovarian Carcinoma (p=0.035; r=0.37)
Conclusion
Expression of CD133 and EGFR were higher in high grade ovarian carcinoma. The higher expression of CD133 will increase
expression of EGFR in ovarian carcinoma. Both markers may be used as prognostic factor.